Ai Enabled Medical Devices Market Report: Market Size & Forecast 2026

The AI-enabled medical devices market encompasses products that integrate machine learning, deep learning, and computer vision into diagnostic imaging equipment, surgical robotics, wearable monitors, clinical decision-support tools, and standalone software regulated as medical devices. The global market reached approximately $15.76 billion in 2025 and is currently estimated at $19.834 billion in 2026, with growth projected at a CAGR of 25.85% through 2031. The market sits within the broader digital and AI-in-healthcare ecosystem, which itself is forecast to expand from roughly $15 billion to nearly $188 billion by 2030.

Demand is being lifted by clinician and patient appetite for earlier and more accurate diagnosis, the proliferation of multimodal healthcare data, and the need to offset workforce shortages through automation. Regulatory progress, notably the FDA's AI/ML-enabled medical device list, which has grown to include more than 1,000 authorized devices, and parallel EU AI Act and MDR frameworks, is shortening time-to-market for compliant products. Reimbursement expansion for AI-assisted imaging and remote monitoring is also converting pilot deployments into recurring commercial revenue.

Segmentation is typically organized by product type (diagnostic imaging, wearables and monitoring, surgical robotics, clinical decision support/SaMD), clinical application (radiology, cardiology, oncology, neurology, pathology), and end user (hospitals, diagnostic centers, ambulatory care, home settings). North America currently leads on revenue and number of FDA-cleared AI devices, followed by Europe, while Asia-Pacific, particularly China, is the fastest-growing regional cluster, with regional CAGR projections above 40% through 2031. Wearables, imaging AI, and SaMD collectively account for the largest share of unit volume.

What are the recent trends and outlook?

Three structural trends will define the next phase: generative and foundation-model AI is moving into clinical documentation, imaging triage, and synthetic data generation; continuous-monitoring wearables are blurring the line between consumer wellness and regulated medical devices; and regulators are formalizing lifecycle expectations for adaptive algorithms, requiring ongoing post-market performance monitoring. As a result, vendors with strong data networks, validated clinical outcomes, and compliant update pipelines are positioned to capture disproportionate share as the market approaches multi-tens-of-billions of dollars by 2031.